MannKind Corporation Logo

MannKind Corporation

MNKD

(2.0)
Stock Price

6,46 USD

2.66% ROA

-9.46% ROE

150.28x PER

Market Cap.

1.776.467.700,00 USD

-106.6% DER

0% Yield

8.07% NPM

MannKind Corporation Stock Analysis

MannKind Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

MannKind Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

MannKind Corporation Price Chart

Chart

Combination chart with 3 data series.
The chart has 2 X axes displaying Time, and navigator-x-axis.
The chart has 3 Y axes displaying values, values, and navigator-y-axis.
View 1 month1mView 3 months3mView 6 months6mView year to dateYTDView 1 year1yView allAllHighcharts.com
End of interactive chart.

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

MannKind Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.91
Net Income per Share
0.04
Price to Earning Ratio
150.28x
Price To Sales Ratio
7.15x
POCF Ratio
43.42
PFCF Ratio
98.79
Price to Book Ratio
-7.81
EV to Sales
8.13
EV Over EBITDA
37.58
EV to Operating CashFlow
49.68
EV to FreeCashFlow
112.23
Earnings Yield
0.01
FreeCashFlow Yield
0.01
Market Cap
1,78 Bil.
Enterprise Value
2,02 Bil.
Graham Number
0.89
Graham NetNet
-1.43

Income Statement Metrics

Net Income per Share
0.04
Income Quality
3.46
ROE
-0.05
Return On Assets
0.05
Return On Capital Employed
0.14
Net Income per EBT
0.86
EBT Per Ebit
0.46
Ebit per Revenue
0.21
Effective Tax Rate
0.14

Margins

Sales, General, & Administrative to Revenue
0.17
Research & Developement to Revenue
0.17
Stock Based Compensation to Revenue
0.08
Gross Profit Margin
0.72
Operating Profit Margin
0.21
Pretax Profit Margin
0.09
Net Profit Margin
0.08

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.15
Free CashFlow per Share
0.07
Capex to Operating CashFlow
0.56
Capex to Revenue
0.09
Capex to Depreciation
3.36
Return on Invested Capital
1.4
Return on Tangible Assets
0.03
Days Sales Outstanding
35.48
Days Payables Outstanding
48.92
Days of Inventory on Hand
126.72
Receivables Turnover
10.29
Payables Turnover
7.46
Inventory Turnover
2.88
Capex per Share
0.08

Balance Sheet

Cash per Share
0,91
Book Value per Share
-0,83
Tangible Book Value per Share
-0.84
Shareholders Equity per Share
-0.83
Interest Debt per Share
1
Debt to Equity
-1.07
Debt to Assets
0.54
Net Debt to EBITDA
4.5
Current Ratio
4.07
Tangible Asset Value
-0,23 Bil.
Net Current Asset Value
-0,34 Bil.
Invested Capital
338109000
Working Capital
0,25 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,02 Bil.
Average Payables
0,01 Bil.
Average Inventory
25597500
Debt to Market Cap
0.14

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

MannKind Corporation Profile

About MannKind Corporation

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

CEO
Dr. Michael E. Castagna Pharm.
Employee
411
Address
30930 Russell Ranch Road
Westlake Village, 91362

MannKind Corporation Executives & BODs

MannKind Corporation Competitors

BioMarin Pharmaceutical Inc. Logo
BioMarin Pharmaceutical Inc.

BMRN

(2.8)
Vaxcyte, Inc. Logo
Vaxcyte, Inc.

PCVX

(0.8)
Liquidia Corporation Logo
Liquidia Corporation

LQDA

(1.8)
Legend Biotech Corporation Logo
Legend Biotech Corporation

LEGN

(2.2)
Bio-Techne Corporation Logo
Bio-Techne Corporation

TECH

(2.5)
United Therapeutics Corporation Logo
United Therapeutics Corporation

UTHR

(3.0)
Larimar Therapeutics, Inc. Logo
Larimar Therapeutics, Inc.

LRMR

(1.5)
Day One Biopharmaceuticals, Inc. Logo
Day One Biopharmaceuticals, Inc.

DAWN

(1.5)
Kiniksa Pharmaceuticals, Ltd. Logo
Kiniksa Pharmaceuticals, Ltd.

KNSA

(1.5)
Verastem, Inc. Logo
Verastem, Inc.

VSTM

(1.2)
ImmunoGen, Inc. Logo
ImmunoGen, Inc.

IMGN

(0.5)
Immutep Limited Logo
Immutep Limited

IMMP

(1.5)
Intercept Pharmaceuticals, Inc. Logo
Intercept Pharmaceuticals, Inc.

ICPT

(1.0)
Elevation Oncology, Inc. Logo
Elevation Oncology, Inc.

ELEV

(1.2)
Acer Therapeutics Inc. Logo
Acer Therapeutics Inc.

ACER

(1.8)
NRx Pharmaceuticals, Inc. Logo
NRx Pharmaceuticals, Inc.

NRXPW

(1.8)
Pasithea Therapeutics Corp. Logo
Pasithea Therapeutics Corp.

KTTA

(1.2)
SAB Biotherapeutics, Inc. Logo
SAB Biotherapeutics, Inc.

SABS

(1.0)
MiNK Therapeutics, Inc. Logo
MiNK Therapeutics, Inc.

INKT

(2.0)
Affimed N.V. Logo
Affimed N.V.

AFMD

(1.2)
Adaptimmune Therapeutics plc Logo
Adaptimmune Therapeutics plc

ADAP

(1.2)
Sangamo Therapeutics, Inc. Logo
Sangamo Therapeutics, Inc.

SGMO

(1.2)